What is REXULTI?
REXULTI (brexpiprazole) is a prescription medication approved by the U.S. Food and Drug Administration (FDA) to treat different conditions related to mental health. Originally approved in 2015, REXULTI is used to treat schizophrenia, bipolar disorder, and major depressive disorder as an adjunct treatment along with other antidepressants. REXULTI works by acting as a partial agonist at serotonin 5-HT1A and dopamine D2 receptors, and as an antagonist at serotonin 5-HT2A receptors.
REXULTI is available in tablets and should only be used under the supervision of a healthcare professional. It may take some time for the medication to start working, and the dosage should be adjusted accordingly by a healthcare professional based on the patient's response and medical condition. It is crucial to follow your healthcare professional's instructions regarding dosage, administration, and possible side effects.
Possible side effects of REXULTI include weight gain, akathisia, headache, nausea, constipation, and insomnia. Before taking REXULTI, patients should inform their healthcare professional about any allergies, medical conditions, or medications they are taking, including over-the-counter and herbal supplements.
It is essential to note that REXULTI may interact with other medications and cause unwanted side effects. Patients should not stop taking REXULTI without consulting their healthcare professional first, as withdrawing from the medication prematurely could lead to adverse effects or a relapse of the mental health condition.
In conclusion, REXULTI is a medication used to treat different mental health conditions and should only be used under the supervision of a qualified healthcare professional. Patients should follow their healthcare professional's instructions regarding dosage, administration, and possible side effects. If a patient experiences any side effects or concerns about their medication's effectiveness, they should talk to their healthcare provider immediately.
Frequently Asked Questions about rexulti
Brexpiprazole is a medication that works in the brain to treat schizophrenia. It is also known as a second generation antipsychotic (SGA) or atypical antipsychotic. Brexpiprazole rebalances dopamine and serotonin to improve thinking, mood, and behavior.
The most common side effects associated with REXULTI plus an antidepressant were weight gain and an inner sense of restlessness such as feeling like you need to move (akathisia), as reported during 6-week clinical studies* of adults with major depressive disorder (MDD).
Compulsive behaviors, including gambling.
Taking Rexulti can cause or increase certain urges, including sexual desires and urges to gamble or binge eat. If you have a history of compulsive behaviors or addiction, talk with your doctor before you start taking Rexulti.
It may not be safe to drink alcohol with Rexulti. This is because drinking alcohol while taking Rexulti may increase your risk of certain side effects from the drug. These include tiredness and slowed thinking, movements, or reactions.
In studies of patients treated for depression with Rexulti, 4% of patients discontinued the treatment due to a weight increase. At the end of a one-year study, patients had gained an average of 3.1 kg (6.8 lb) from the start of the study.
This medication is used to treat certain mental/mood disorders (such as schizophrenia, depression). Brexpiprazole is also used to treat agitation that may occur with dementia due to Alzheimer's disease. Brexpiprazole helps you to think more clearly, feel less nervous, and take part in everyday life.
In clinical studies, 6% to 8% of people taking Rexulti for depression had weight gain. In comparison, 2% of people taking a placebo (treatment with no active drug) had weight gain. People who took Rexulti gained an average of 2.8 to 3.5 pounds (1.3 to 1.6 kilograms), depending on their dose of the drug.
It's possible that Rexulti may make you feel tired. In studies, fatigue (lack of energy) and drowsiness were reported by people taking Rexulti to treat depression. Keep in mind that for depression, Rexulti is prescribed along with antidepressant medication. Tiredness is a side effect of antidepressants as well.
In clinical studies, 6% to 8% of people taking Rexulti for depression had weight gain. In comparison, 2% of people taking a placebo (treatment with no active drug) had weight gain. People who took Rexulti gained an average of 2.8 to 3.5 pounds (1.3 to 1.6 kilograms), depending on their dose of the drug.
In clinical studies, 6% to 8% of people taking Rexulti for depression had weight gain. In comparison, 2% of people taking a placebo (treatment with no active drug) had weight gain. People who took Rexulti gained an average of 2.8 to 3.5 pounds (1.3 to 1.6 kilograms), depending on their dose of the drug.
In studies of patients treated for depression with Rexulti, 4% of patients discontinued the treatment due to a weight increase. At the end of a one-year study, patients had gained an average of 3.1 kg (6.8 lb) from the start of the study.
Weight loss
Some people in certain clinical studies reported losing weight while taking Rexulti. However, these people may have lost weight due to other reasons. The studies that reported this weight loss weren't designed to show the side effects caused by Rexulti.
Rexulti may lower a person's mood and increase suicidal thoughts. Tell your doctor if you have ever had problems with mood or depression. You and your family members should be on alert for signs of worsening depression, suicidal thoughts, or other mood changes.
Schizophrenia studies
At the end of a one-year study, patients had gained an average of 2 kg (4.4 lb) from the start of the study. Results showed 20% of patients had a 7% or greater increase in body weight, while 10% had a 7% or greater decrease in body weight.
In a 12-week long extension study after the initial 12 week treatment period, there was no mean change in weight (kg) from baseline to last visit. Four percent of patients demonstrated at least a 7% increase in body weight, and 5% showed at least a 7% decrease in body weight from baseline to last visit.
In a 12-week long extension study after the initial 12 week treatment period, there was no mean change in weight (kg) from baseline to last visit. Four percent of patients demonstrated at least a 7% increase in body weight, and 5% showed at least a 7% decrease in body weight from baseline to last visit.
